Rhône-Poulenc Rorer (RPR) is a global pharmaceutical company dedicated to improving human health. The Company had sales of $5.4 billion and invested $882 million in Research and Development in 1996.

Rhône-Poulenc Rorer is committed to innovation to meet unmet medical needs. RPR is at the forefront of research in areas such as resistant microbial infections, the treatment of cancers, promising new treatments in cardiology and innovative treatments for respiratory and allergy diseases. RPR is also developing new drugs in the areas of women's health and central nervous system disorders.

Rhône-Poulenc Rorer has developed and marketed Imovane® (zopiclone), also known as Amoban®, Zimovane®, Ximovan® and Limovan®, to treat insomnia including difficulties in falling asleep, nocturnal awakenings and early morning awakening. Zopiclone is the leader of a class of psychotropic agents, the cyclopyrrolones.

For additional information about Rhône-Poulenc Rorer, please visit their site on the World Wide Web at: